Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Abstract Non-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs) against programmed cell death 1 (PD-1/L1) axis are to provide long-term survival...

Full description

Bibliographic Details
Main Authors: Zhenbin Qiu, Zihao Chen, Chao Zhang, Wenzhao Zhong
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Experimental Hematology & Oncology
Subjects:
Checkpoint inhibitors
NSCLC
Novel therapies
Online Access:http://link.springer.com/article/10.1186/s40164-019-0143-z

Internet

http://link.springer.com/article/10.1186/s40164-019-0143-z

Similar Items